У нас вы можете посмотреть бесплатно Update From AACR-NCI-EORTC: PYNNACLE phase 2 study или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Drs Alison Schram and Elena Garralda share expert insights on the PYNNACLE Phase 2 initial analysis at AACR–NCI–EORTC 2025. The PYNNACLE phase 2 study evaluates rezatapopt, a first-in-class p53 reactivator, as a treatment for TP53 Y220C–mutant advanced solid tumours. In this video, the experts discuss: • TP53 Y220C mutation and the rationale for mutant p53 reactivation • Study overview and practice implications, spotlighting ovarian cancer • Testing strategies for early and accurate patient identification *Rezatapopt is an investigational agent which is not approved by a regulatory agency Visit the COR2ED website to learn more and download the accompanying slides and poster for more information here: https://cor2ed.com/n-connect/programm... Clinical takeaways: • Reactivating p53 Y220C protein is a promising therapeutic strategy for patients with solid tumours specifically ovarian cancer, with TP53 Y220C mutations, where effective targeted therapies and biomarkers are limited. • Rezatapopt is a first-in-class investigational p53 reactivator that selectively binds to the mutated p53 Y220C protein, stabilising its structure to restore wild-type tumour suppressor activity. • Rezatapopt demonstrates rapid, durable and broad antitumour activity in TP53 Y220C–mutant solid tumours, with a particularly strong signal in ovarian cancer, and a generally manageable safety profile. • Looking ahead, it will be important to prioritise early and accurate identification through up-front comprehensive genomic profiling using NGS with TP53 gene coverage. Tissue is preferred; when tissue is limited, selected ctDNA assays capable of excluding CHIP may be used. This programme has been sponsored by PMV Pharma Published October 2025